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Background: Despite current trend of targeted therapy development, cytotoxic agents are a mainstay of treatment of
patients with breast cancer. We reviewed recent advances in cytotoxic therapy for patients with metastatic breast
cancer (MBC).
Materials and methods: Medline searches were conducted for English language studies using the term ‘MBC’ and
‘cytotoxic drugs’. The data search was restricted to the period 2000–2011.
Results: Several novel cytotoxic compounds, all microtubule inhibitors, have been approved for clinical use in MBC:
(i) nab-paclitaxel, reported to improve tumour response and decrease hypersensitivity reactions in comparison with
other taxanes; (ii) ixabepilone, shown to have clinical benefit in taxane- and anthracycline-resistant disease and
(iii) eribulin, shown to improve overall survival in heavily pre-treated patients, when compared with best available
standard treatment. Agents, such as larotaxel, vinflunine, trabectidin and formulations, including cationic liposomal
paclitaxel or paclitaxel poliglumex, are currently under evaluation in phase II/III trials.
Conclusion: Toxicity and chemotherapy resistance are still major limitations in the treatment of patients with MBC.
Further research into new cytotoxic compounds is needed in order to maximise benefit, whilst minimising toxicity.
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introduction
As the second most common cancer-related cause of death
among females, breast cancer is considered a major public
health concern [1]. Despite an improvement in overall survival
(OS), with the use of anthracyclines and taxanes, resistance to
therapy and subsequent progression of disease are still observed
in metastatic patients [2]. Thus, it is clear that new agents and
treatment strategies are needed.
This review aims to evaluate all available data regarding
cytotoxic therapy for breast cancer.
methods
Medline searches were conducted for English language studies in cancer
patients using the terms ‘breast cancer’ and ‘cytotoxic agents’. These
searches were supplemented by reference list searches, the Cochrane
database, American Society of Clinical Oncology and European Society for
Medical Oncology abstracts and consultation with experts in the field.
Studies meeting the following criteria were selected: prospective phase I, II
and III clinical trials of chemotherapy (weekly or daily schedules), including
indicators of activity and toxicity, data on survival/mortality and at least
one multivariate analysis examining survival.
results
All results retrieved are classified by pharmacological type and
further described with a focus on the mechanism of action,
evidence of efficacy and the toxicity profile. Ongoing major
trials are summarised in Table 1.
antimicrotubule agents
Microtubule inhibitors are among the most frequently used
agents for breast cancer chemotherapy, with proven efficacy in
both localised and metastatic disease [18]. However, the risk of
hypersensitivity reactions and other severe adverse events
impairing quality of life, together with susceptibility to
resistance [19], are concerning limitations to their use. Another
issue related to this class of agents is peripheral sensory
neuropathy, in most of the cases dose-limiting toxicity for
patients with metastatic breast cancer (MBC). For this reason,
research into alternatives has intensified, thus resulting in the
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Table 1. Major clinical trials involving novel cytotoxic agents
Agents Study Reference N Phase/patients Response Grade 3/4 toxicity
Nab-P Gradishar et al. [3] - 460 III; metastatic, ABI-007
versus P
ORR: 33% versus 19%
(P = 0.001); OS: 65.0
versus 55.7 weeks
(P = 0.374)
Neutropaenia G4: 9 versus
22%; neuropathy
G3: 10 versus 2%
Gradishar et al. [4] - 302 II; first line; ABI-007 versus
docetaxel
PFS: 12.9 versus 7.5 m
(P = 0.0065) for
weekly ABI-007
Neutropaenia G4: 5 versus
75%; neuropathy G3:
comparable (not stated)
Ongoing trial - 203 II; adjuvant; AC followed by
P or ABI-007
Primary end points: safety NCT ID number:
NCT00394251
P-poliglumex Lin [5] - 18 II; metastatic, first or second
lines
Trial suspended due
to high rate of
adverse events
Hypersensitivity: 22%;
neuropathy: 22%
EndoTAG1 Awada [6] - 143 II; metastatic, first
or second lines,
ET + P, ET or P
PFS at 16 weeks: 4.2, 3.4
and 3.7 m, respectively;
OR: 25%, 5% and 38%
Neutropaenia G3/4: 20%
(combination group);
chills and fever
related to ET
Larotaxel Die´ras et al. [7] - 130 II; metastatic, first
or second lines
Resistant to taxanes—ORR:
19%; TTP: 1.6 m;
Non-resistant—ORR:
42%; TTP: 5.4 months
Neutropaenia: 82%;
neuropathy: 7%;
diarrhoea: 12%
Ongoing trial – 438 III; metastatic, late-line,
larotaxel versus
capecitabine
Primary end points: TTP;
secondary end points: OS
NCT ID number:
NCT00081796
Ixabepilone Trial 009 [8] 49 II; metastatic, late-linea
monotherapy
ORR: 12%; SD: 41%;
DOR: 10.4 m;
TTP 2.2 m; OS 7.9 m
Fatigue G3: 27%;
neuropathy G3: 12%;
myalgia G3: 10%;
neutropaenia: 53%;
febrile neutropaenia: 6%
Trial 081 [9] 113 II; metastatic, late-line
monotherapy
ORR: 11.5%; SD: 50%;
DOR: 5.7 m; PFS 3.1 m;
OS 8.6 m
Neutropaenia: 54%; febrile
neutropaenia: 3%;
neuropathy: 13%;
fatigue/asthenia: 14%
Trail 046 [10] 737 III; metastatic, late line;
resistant A/T Ixa/Cap
versus Cap
ORR: 34.7% versus 14.3%;
DOR: 6.4 versus 5.6 m;
PFS 5.8 versus 4.2 m;
HR: 0.75
Neuropathy: 21%;
hand–foot syndrome
G3: 8%;
neutropaenia: 68%;
febrile neutropaenia: 5%a
Trial 048 [11] 1221 III; metastatic; late-line
pre-treated A/T; Ixa/Cap
versus Cap
OS: 16.4 versus 15.6 m;
PFS: 6.2 versus 4.2 m;
RR: 43% versus 29%
Neuropathy: 24%;
hand–foot syndrome: 21%;
diarrhoea: 43%;
neutropaenia: 73%
VFL Campone et al. [12] [12] 60 II; metastatic, late line; ORR: 30%; SD: 35%;
PFS: 3.7 m; OS: 14.3 m
Neutropaenia: 65%;
Constipation G3: 11.7%
Yardley et al. [13] [13] 31 II; metastatic, first line,
addition of trastuzumab
according to
HER2 status
VFL + trastuzumab—
ORR: 48%; PFS: 6.6 m;
OS not reached;
VFL—PFS: 3.5 m;
OS: 9 m
VFL +
trastuzumab—neutropaenia
G4: 24%; nausea/vomiting G3:
29%; VFL—neutropaenia G4:
9%; nausea/vomiting G3: 0%
Ongoing trial – 764 Plan III; metastatic,
late line
Primary end points: PFS;
secondary end points:
OS, ORR, safety, QoL
NCT ID number:
NCT01095003
Eribulin Cortes et al. [14] [14] 299 II; metastatic,
late line
ORR: 9.3%; SD: 46.5%;
PFS: 2.6 m
Neutropaenia: 54%; febrile
neutropaenia: 5.5%;
neuropathy: 6.9%
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discovery of the following new compounds and more tolerable
formulations of paclitaxel.
new taxane formulations
nab-paclitaxel. mechanism of action. Agents, such as nab-
paclitaxel (ABI-007 or Abraxane), were developed in an
attempt to avoid the hypersensitivity reactions associated with
taxanes, which are related to the solvent suspension in
polyoxyethylated castor oil (cremophor). ABI-007 consists of
a colloidal formulation, prepared by homogenisation of
paclitaxel in human serum albumin at a concentration of 3%–
4% [20]. The resulting nanoparticles form systemic albumin-
bound complexes, which potentially deliver higher intracellular
concentrations of taxane [20].
activity. In phase I studies, the maximum dose of nab-
paclitaxel is reported as 300 mg/m2 every 3 weeks; thus, there
is delivery of a higher dosage than by cremophor paclitaxel
[20]. The USA FDA (Food and Drug Administration) granted
approval for the use of ABI-007 in clinical practice following
a phase III multicentre, open-labelled trial, involving 460
patients with MBC. ABI-007 (dose of 260 mg/m2 at 21-day
intervals) was compared with 175 mg/m2 paclitaxel every 3
weeks [3]. The primary outcome measurements demonstrated
a benefit with nab-paclitaxel, which was statistically
significant in all patients, in terms of overall response rate
(ORR) (33% versus 19%; P = 0.001) and time to progression
(TTP) [23.0 versus 16.9 weeks; hazard ratio (HR) = 0.75;
P = 0.006]. A small improvement was suggested in median
survival, though this was not significant (65.0 versus 55.7
weeks; P = 0.374). A phase II trial compared nab-paclitaxel as
first-line therapy in three distinct regimens (300 mg/m2 3
weekly, weekly 100 or 150 mg/m2), with docetaxel (100 mg/m2
3 weekly). Authors reported an improvement in progression-free
survival (PFS) of 12.9 versus 7.5 months (P = 0.0065) with the
weekly regimen of ABI-007 [4]. In our opinion, the right dose
and the right schedule is still not determined and this is
a potential limitation for clinical development of this drug in the
early, neoadjuvant setting.
toxicity. Relative to cremophor paclitaxel, ABI-007 is
reportedly associated with reduced myelotoxicity and with
5%–9% grade 4 neutropaenia, but with a greater incidence
of grade 3 neuropathy (10% versus 2% for paclitaxel) [3, 4].
However, there are fewer reported instances of
hypersensitivity reactions. Gradishar et al. [3] described the
use of corticosteroid and anti-histamine premedication (for
emesis, myalgia/arthralgia or anorexia) in 99% of patients
administered paclitaxel, in comparison with 8% from the
nab-paclitaxel group.
paclitaxel poliglumex. mechanism of action: Paclitaxel
poliglumex (CT-2103) is also a conjugate compound, in this
case with paclitaxel bound to a-poly-L-glutamic acid. This
formulation was developed with the aim of improving selective
delivery of the drug to neoplastic tissue, thus increasing
efficacy.
activity: This compound is more extensively studied in non-
small-cell-lung cancer [21], with little research conducted for
breast cancer. A phase II trial of 18 patients with HER2-
negative MBC was suspended as rates of neurotoxicity and late
hypersensitivity reactions were much higher than expected [5].
toxicity: As stated above, hypersensitivity reactions and
neuropathy were common, occurring in 4 of 18 patients [5].
However, this same schedule has been widely studied for other
tumours and been found to have an acceptable tolerability profile
[22].
cationic liposomal paclitaxel. mechanism of action:
With a similar concept to liposomal anthracyclines, in which
the cytotoxic agent is encapsulated by a phospholipid membrane,
liposomal formulations containing paclitaxel were created with the
aim of minimising toxicity. In preclinical studies, liposomal taxanes
modify pharmacodynamics but maintain similar antitumoural
activity [23]. Moreover, in animal models, cationic liposomes were
targeted to negatively charged activated endothelial cells of tumour
vessels, thus altering drug delivery [24].
activity: The first phase II randomised trial involving the use
of cationic liposomal paclitaxel (EndoTAG-1) enrolled 143
patients with triple-negative (TN) MBC in first- or second-line
Table 1. (Continued)
Agents Study Reference N Phase/patients Response Grade 3/4 toxicity
EMBRACE (2011) [15] 762 III; metastatic,
late line
OS: benefit of 2.5 m;
HR: 0.81 (P = 0.04)
Neutropaenia: 44%;
neuropathy: 8.4%
Study 301 [16] 1102 III; metastatic,
capecitabine
versus E7389
Primary end points:
OS and PFS
(Ongoing trial); NCT ID
number: NCT00337103
Trabectidin Zelek et al. [17] - 27 II; metastatic,
late line
ORR: 14%; TTP: 2.14 m;
OS: 10 m
Neutropaenia G4: 33%;
transaminitis: 75%
aReported toxic effects occurring in the combination arm.
Cap, capecitabine; DOR, Duration of response; ET, EndoTAG1; HR, hazard ratio; m, months; Ixa, ixabepilone; NCT ID, tracking identification number
from clinicaltrials.gov; ORR, overall response rate; OR, objective response; OS, overall survival; PFS, progression-free survival; P, paclitaxel; QoL, quality of
life; RR, response rate; SD, stable disease; TTP, time to progression; VFL, vinflunine.
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therapy to a three-arm 2:2:1 study of EndoTAG-1 plus
paclitaxel, isolated EndoTAG-1 or paclitaxel [6]. Preliminary
analysis showed a PFS of 4.2, 3.2 and 3.7 months and objective
response of 25%, 5% and 38%, respectively. Longer follow-up is
needed to better define whether such a combination offers
advantage in terms of efficacy, as well as toxicity.
toxicity: EndoTAG-1 has been associated with fever and
chills, although a tolerable toxicity profile is reported on phase II
studies [6, 25]. The ongoing trial, above described, observed 20%
grade 3/4 neutropaenia with the cremophor paclitaxel preparation.
new taxanes: larotaxel.
mechanism of action: Larotaxel (XRP 9881) is a semisynthetic
taxoid derived from the natural compound 10-deacetyl
baccatin III, extracted from the tree Taxus baccata. Its
mechanism of action is similar to that of other taxanes: it
aggregates tubulin and inhibits microtubule dynamics.
Additionally, evidence supports its action in taxane-resistant
cells [26] and its ability to cross the blood–brain barrier in
animal experiments [27].
activity: In phase I preclinical studies, the most well-
tolerated dosage regimen was 90 mg/m2 every 3 weeks [28].
Other schedules evaluated were the same dose on days 1 and 8
of each 21-day cycle [29], in which the main limiting toxicity
was diarrhoea [30]. The largest phase II trial (n = 130) studied
the use of 1-h infusions of 90 mg/m2 larotaxel every 3 weeks.
All patients had previously been treated with taxane as
adjuvant, neoadjuvant or first-line therapy and were stratified
as resistant or non-resistant in accordance with their
response. The ORR was 42% and the TTP 5.4 months in the
non-resistant group; while in the resistant group, the ORR
was 19% and the TTP 1.6 months, thus showing that larotaxel
retained minimal benefit in patients previously exposed to
taxanes [7].
toxicity: Myelotoxicity is the major side-effect with the use of
this agent. The most common grade 3/4 adverse events,
documented by Die´ras et al. [7], were neutropaenia (82%),
febrile neutropaenia (9%) and sensory neuropathy (7%). Grade
3/4 diarrhoea was reported in 12% of patients. Seventeen
patients discontinued larotaxel due to side-effects.
epothilones
Originally isolated from myxobacterium Sorangium cellulosum
[31], the epothilones are macrolide compounds with strong
antitumour activity against several human cancer cell types
[32]. Currently, there are five epothilones undergoing
investigation in clinical trials: ixabepilone, patupilone, BMS-
310705, KOS-852 and ZK-EPO [33]. One of the most active
epothilone analogues is ixabepilone, which has been evaluated
in combination or monotherapy for MBC.
ixabepilone. mechanism of action: Epothilones are strong
promoters of tubulin polymerisation in vitro [34], enhancing
microtubule stability and the formation of abnormal mitotic
spindles, which induce G2–M cell cycle arrest and apoptosis.
Structural analysis indicates that epothilones may bind at or
near the paclitaxel binding site on the b-tubulin protein [35]
having, however, different characteristics for microtubule
binding interaction [36].
activity: ixabepilone monotherapy. The best tolerated
regimen in phase I preclinical studies was 40 mg/m2 every 21
days [37]. A phase II randomised trial, comparing a weekly
schedule with a 3-weekly schedule, demonstrated a trend
towards a longer PFS for the 3-week regimen, although
weekly ixabepilone was better tolerated [38]. Two key phase
II clinical trials evaluated ixabepilone in a highly refractory
population, showing significant activity. The 009-phase II
trial enrolled 49 patients with MBC [8] receiving 40 mg/m2
ixabepilone, infused over 3 h, every 21 days. Efficacy analysis
reported an ORR of 12% with a median duration of response
of 10.4 months and stable disease (SD) in 41%. Median TTP
was 2.2 months [95% confidence intervals (CI): 1.4–3.2
months]. Another phase II trial assessed ixabepilone in 126
patients, using the same treatment schedule [9]. In the 113
assessable patients, the ORR was 11.5%. The median
duration of response was 5.7 months (95% CI: 4.4–7.3
months) and the median PFS 3.1 months (95% CI: 6.9–11.1
months).
ixabepilone combination regimens. capecitabine: The
biological rational behind this combination is a synergistic
interaction as a consequence of enhanced expression of
thymidine phosphorylase [39, 40]. The activity of this
association was shown in a phase II trial assessing 62 patients
previously treated with anthracycline and taxane (Table 2).
The preliminary results were encouraging, hence prompting
phase III trials [40]. The CA163-046 study enrolled 752
patients with MBC resistant to anthracyclines and taxane
[10], randomised to receive either the combination treatment
(40 mg/m2 ixabepilone, infused over 3 h on day 1 plus 2000
mg/m2 capecitabine on days 1–14 of a 21-day cycle) or the
capecitabine monotherapy (2500 mg/m2 on days 1–14 of
a 21-day cycle). A significant increase in PFS (5.8 versus 4.2
months; HR = 0.75; P = 0.0003) and ORR (35% versus 14%; P
< 0.0001) was seen in the combination arm compared with
the monotherapy arm. Furthermore, SD was recorded in 41%
versus 46% of patients. A second phase III (CA163-048) trial
with the same design was conducted with 1221 patients with
MBC, who were anthracycline and taxane pre-treated, but not
necessarily chemotherapy resistant [11]. No significant
difference in OS was observed (16.4 versus 15.6 months; HR
= 0.9; 95% CI, 0.75–1.03; P = 0.1162). PFS (6.2 versus 4.2
months; HR = 0.79; P = 0.0005) and response rate (RR) (43%
versus 29%; P < 0.0001) were improved. Other combinations
are being tested in phase I/II trials, namely, with epirubicin,
and to date demonstrate an acceptable safety profile [41]. A
randomised clinical trial (PAC 8) in the neoadjuvant setting
comparing ixabepilone to weekly paclitaxel was recently
prematurely closed due to futility.
bevacizumab: A phase II, randomised study in 123 HER2-
negative MBC patients compared weekly versus 3-weekly
ixabepilone plus bevacizumab (ixa/bev), versus paclitaxel
plus bevacizumab (pac/bev) as first-line therapy [42]. The
ORR was 48% (95% CI: 32.9% to 63.1%) in the weekly ixa/
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Table 2. Summarised data for cytotoxic agents: mechanism, Supporting evidence, status and disadvantages
Class Agents Mechanism Supporting evidence Developmental status Main side-effects
Antimicrotubules
Taxanes New formulations
Nab-paclitaxel Paclitaxel in
albumin-bound
complexes
Better response rates FDA and EMA
approval for
metastatic setting
Increased neurotoxicity
Less need to
premedicate
Ongoing trials on
adjuvant and
neoadjuvant
treatment
Related reports
of cystoid
macular oedemaLess neutropaenia
Alopecia: 33%
Paclitaxel
poliglumex
Paclitaxel conjugated to
a-poly-L-glutamic acid
Lacking evidence
for breast cancer
New ongoing
phase II trials
Higher neurotoxicity
and hypersensitivity
in a small phase
II study
Hair thinning: 7%
Cationic
liposomal
paclitaxel
Paclitaxel in
positively
charged
liposomes
Lacking evidence
of benefit
Need to evaluate
this drug in other
breast cancer
subtypes
Fever and chills
(reported tolerability)
Possible superiority
when combined
with classical
paclitaxel
Association to
classical paclitaxel:
increased neutropaenia
(20%)
New agents
Larotaxel Similar to
other taxanes
Activity observed
in taxane
resistance
Ongoing phase III trial
to compare with
capecitabine
Increased frequency
of neutropaenia (82%)
High rates of grade 3/4
diarrhoea
Alopecia: 84%
Distinct agents Eribulin Tubulin destabilisation:
unknown site of action
Survival benefit
in late-line
regimen
Ongoing phase
III trial to compare
with capecitabine
Increased frequency
of neutropaenia
(44%–54%)
Activity observed
in taxane resistance
FDA and EMA approval
for metastatic setting
Alopecia: 60%
Vinca alkaloids Vinflunine Similar to
other vinca
alkaloids
Activity observed
in taxane resistance
Ongoing phase
III trial testing
combination treatment
with capecitabine,
another comparing
paclitaxel/gemcitabine
versus gemcitabine/
vinflunine
Increased frequency
of neutropaenia
(up to 65%)
Less neurotoxicity Alopecia: 55%
Epothilones Ixabepilone Promoters of
tubulin polymerisation,
enhancing microtubule
stability
Activity observed
in taxane resistance
FDA approval for
metastatic setting
Toxicity profile similar
to other taxanes
Ongoing trials on
neoadjuvant and
metastatic setting
with epirubicin,
bevacizumab,
trastuzumab
Alopecia: 84%
Alkylating agents
Trabectidin DNA-interacting
agent and
transcription inhibitor
Activity in
phase II trial
Ongoing phase II trial
testing trabectidin
in HER2-positive and
BRCA1/BRCA2
mutation carriers
Grade 4
neutropaenia (33%)
and hepatitis (44%)
FDA, Food and Drug Administration.
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bev arm, 71% (95% CI: 55.7% to 83.6%) in the 3-weekly ixa/
bev arm and 63% (95% CI: 43.7% to 78.9%) in the pac/bev
arm. In terms of toxicity, a higher frequency of grade 3/4
neutropaenia was observed with the 3-weekly ixa/bev regimen
(60% versus 22% for pac/bev and 16% for weekly ixa/bev);
however, rates of peripheral neuropathy were similar.
trastuzumab: The efficacy of ixabepilone with trastuzumab
was investigated in a non-randomised, phase II study
conducted in 39 patients with HER2-positive MBC. The
patients enrolled received this combination as first-line
therapy or following one or two trastuzumab-containing
regimens[43]. The RR was 51%. Neuropathy was the major
toxicity (grade 2 ‡55%). There were no cardiac toxicity
episodes of grade 2 or greater. In another phase II trial of
trastuzumab, weekly ixabepilone and carboplatin were
administered in first-line setting to 59 patients with HER2-
positive MBC [44]. The ORR was 42%, with median PFS of 8
months, and one death related to therapeutic complications.
toxicity: The most common toxicity with ixabepilone
monotherapy is myelosuppression, primarily neutropaenia,
although peripheral sensory neuropathy is also reported
(grade 3/4: 7%–20%), and, rarely, febrile neutropaenia [45].
Combination regimens with capecitabine were well tolerated
with minimal overlapping toxic effects. The most frequently
reported grade 3/4 non-haematological adverse events were
peripheral sensory neuropathy (21%–23%), hand–foot
syndrome (18%–21%), fatigue (9%–12%) and diarrhoea
(6%–7%). Myelosuppression was common and consisted
primarily of leucopaenia and neutropaenia, with a low
incidence of febrile neutropaenia (5%–7%) [10, 11].
Sensory neuropathy is a major issue for this class of agents.
A major adverse effect of treatment with microtubule-
stabilising agents, such as epothilones, is peripheral neuropathy,
which is probably caused by the interruption of axonal
transport induced by microtubule-stabilising agents. The
development of neuropathy can be dose or treatment limiting
for many cancer patients, and neuropathy can lead to
permanent neuronal dysfunction in a minority of patients.
Identification of clinical tools to predict and intervention
trial to prevent neurotoxicity are key areas of research.
new vinca alkaloids
vinflunine. mechanism of action: Synthesised in 1997,
vinflunine is one of the newest vinca alkaloids in this review.
The chemotoxicity of this agent is primarily through the
depolymerisation of tubulin compounds leading to formation
of tubulin paracrystals, although additional anti-angiogenic
properties have been observed in vitro [46].
activity: Phase II studies of other neoplasms have
demonstrated an optimum starting dose of 320 mg/m2
vinflunine every 3 weeks [47], although the maximum dose is
reported as 400 mg/m2 [48]. The first phase II trial in breast
cancer evaluated vinflunine at a dose of 320 mg/m2 every 21
days in 60 patients, with metastatic disease, who had
progressed following taxane and anthracycline therapy [12].
This study indicated benefit in this particular group, with an
ORR of 30% and SD achieved in 35% of patients, as well as
PFS of 3.7 months and an OS of 14.3 months. Two recent
trials analysed a combination of vinflunine and trastuzumab
therapy in a metastatic setting: the first, a phase I study of 30
HER2-positive patients, assessed the dosage and safety of
vinflunine (280 or 320 mg/m2 every 3 weeks) with
trastuzumab (loading dose of 4 mg/kg and subsequently 2
mg/kg/week) [49]. Interim analysis showed RRs of 62.5% and
73.7% in patients receiving vinflunine at 280 and 320 mg/m2,
respectively, with adequate safety. A subsequent phase II,
non-randomised, open-labelled trial of 31 HER2-positive
patients evaluated combination (280 mg/m2 vinflunine plus
6 mg/kg trastuzumab 3 weekly) or monotherapy (320 mg/m2
vinflunine) [13]. For those 20 patients receiving combination
therapy, there was a partial response (PR) in 48%, with PFS
of 6.6 months. All these results are in line with other data
showing the potential benefit of giving trastuzumab beyond
progression, even if available data in this field are limited. In
primary analysis for monotherapy patients, there was median
PFS of 3.5 months and OS of 9 months.
toxicity: The main toxicity noted during monotherapy with
320 mg/m2 vinflunine was grade 3/4 neutropaenia, observed
in 65% [12]. Grade 3 constipation in 11% of patients was
also reported by Campone et al. [12]. The addition of
trastuzumab resulted in a significant increase in grade 4
neutropaenia (24% versus 9%) and grade 3 nausea and
vomiting (29% versus 0%) [13].
Eribulin. mechanism of action: Eribulin mesylate (E7389) is
a synthetic analogue of halichondrin B, a polyether macrolide
originally extracted from the marine sponge Halichondria
okadaic [50, 51]. Polymerisation is inhibited by eribulin,
causing aggregation of tubulin into non-functional units,
hence leading to destabilisation of microtubules; in contrast,
classical compounds act to stabilise tubulin.
activity: Phase I and II trials have demonstrated a maximum
dose of 1.4 mg/m2, initially administered at days 1, 8 and
15 of a 28-day cycle [52] but later used in 21-day regimens
to decrease myelotoxicity [53]. A recent phase II trial
administered eribulin at days 1 and 8 of a 21-day cycle to 299
patients, with manageable toxicity, and primary end points
reported as an ORR of 9.3% and SD rates of 46.5% [14]. The
first study to analyse OS was the recent phase III trial
EMBRACE of 762 patients with MBC previously exposed to
anthracycline and taxanes, comparing eribulin (regimen as
above) to treatment of physician’s choice (TPC) (either
monotherapy or supportive care). In primary analysis, there
was a statistically significant benefit conferred by the use of
eribulin, with an absolute gain of 2.5 months in survival (HR =
0.81; 95% CI: 0.66–0.99; P = 0.04) [15]. OS was significantly
improved in women assigned to eribulin (median 13.1 months,
95% CI: 11.8–14.3) compared with (TPC) (10.6 months, 9.3–
12.5; HR = 0.81, 95% CI: 0.66–0.99; P = 0.041).
toxicity: The most common adverse events in both groups
were asthenia or fatigue [270 (54%) of 503 patients on eribulin
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and 98 (40%) of 247 patients on TPC at all grades] and
neutropaenia [260 (52%) patients receiving eribulin and 73
(30%) of those on TPC at all grades]. Peripheral neuropathy
was the most common adverse event leading to
discontinuation from eribulin, occurring in 24 (5%) of 503
patients. [15].
alkylating agents
Trabectidin (ET-743). mechanism of action: Trabectidin is
a marine-derived DNA-interacting agent and transcription
inhibitor found in the ascidian Ecteinascidia turbinate [17].
Evidence supports ET-743 as an effective agent, acting by
down-regulation of P-glycoprotein/MDR1 and by
immunomodulation (having an inhibitory effect on
macrophage viability, differentiation and cytokine
production) [54].
activity: Following promising findings in phase I studies
[55], a multicentre, open-labelled, phase II non-randomised
trial assessed the activity of trabectidin and the feasibility of
its use in 27 women with advanced breast cancer previously
treated with anthracyclines and/or taxanes [17]. Trabectidin,
as a 24-h infusion of 1.5 mg/m2, was administered at 3-week
intervals. Twenty-two patients (81.5%) were assessable for
response. The ORR was 14% (95% CI: 3.5% to 32%), with
a median survival of 10 months (95% CI: 4.88–15.18
months). Six patients had SD. Preclinical and clinical data
reporting a better outcome in sarcoma patients with low
levels of BRCA1 [56] prompted a phase II trial of trabectidin
in 95 patients with TN (group A), HER2-positive (group B)
and BRCA1/2 germ line (group C) mutated MBC.
Trabectidin was given at a dose of 1.3 mg/m2, as a 3-h i.v.
infusion every 2 weeks. Data were available for 72 patients.
Trial accrual was closed due to no activity in TN MBC [57]. A
total of 55 patients were enrolled in groups B (n = 31) and C
(n = 24) with a PR in 10% and 14% and disease remaining
stable in 58.6% and 38.1%, respectively. Median PFS was 3.9
months in each arm [58].
toxicity: The most common observed toxic effects with
trabectidin use were grade 3 neutropaenia (33%) and
transaminitis (44%) [17]. Neutropaenic fever did not arise and
although transaminitis occurred in the majority of patients, it
led to no serious clinical events. It is worth mentioning that the
absence of other severe toxic effects, namely, grades 3–4
alopecia, and the lack of cumulative toxic effects make
trabectidin attractive for long-term palliative use.
discussion
In attempt to overcome chemotherapy resistance, new agents
have been developed for therapy in patients with MBC. Two
novel cytotoxic compounds are currently approved by USA
FDA, both with antimicrotubule activity. The first,
ixabepilone, either in monotherapy after previous exposure to
anthracycline, taxane and capecitabine (ORR 11.5% and PFS
3.1 months) [9] or in combination with capecitabine, was
accepted based on benefit observed in PFS (relative increment
of 25%) and ORR (35% versus 14%) in patients resistant to
anthracycline and taxane [10]. The European Medicine
Agency (EMA) Committee for Medicinal Products for
Human Use (CHMP) adopted a negative opinion of the
marketing authorisation for ixabepilone (2 mg/ml powder
and solvent for concentrate for solution for infusion)
intended to treat locally advanced or MBC and recommended
that it be refused. The CHMP recommended that ixabepilone
be refused marketing authorisation because it was
concerned that ixabepilone’s benefits in terms of increasing
TTP and the very small increase in survival rates did not
outweigh concerns over the medicine’s safety. In particular,
the Committee was concerned over neuropathy, which was
a severe and common side-effect in patients taking the
medicine. The second agent is eribulin, recently approved in
taxane- and anthracycline-resistant disease, after primary
outcome measures from the EMBRACE trial, in which
a statistically significant improvement in OS of 2.5 months
was observed [15]. Neutropaenia was the most frequent
adverse grade 3/4 event (54%) recorded for either drug,
together with sensory neuropathy (21%–24% in ixabepilone
and 8.4% in eribulin) [8, 15]. Following phase II studies
demonstrating activity on refractory disease, other agents
deemed to hold promise were larotaxel and vinflunine.
Approved by FDA and EMA for clinical application in
anthracycline-resistant disease since 2005, nab-paclitaxel, an
alternative taxane formulation, is associated with fewer
hypersensitivity reactions and significantly less myelotoxicity,
in comparison to castor oil paclitaxel (9 versus 22%),
however greater grade 3 neuropathy (10% versus 2%) [6]. In
contrast to standard paclitaxel, nab-paclitaxel was
characterised by a greater ORR (33% versus 19%) and TTP
(HR = 0.75), though benefit on OS cannot be yet proven
statistically. Such favourable results led to the initiation of
a study, not yet completed, of nab-paclitaxel in localised
breast cancer. A disadvantage of nab-paclitaxel is cost, which
is up to five times higher than the standard formulation, and
reported to be comparable to docetaxel in overall cost
analysis [59, 60].
Summary of supporting evidence and disadvantages of
cytotoxic agents are presented in Table 2.
conclusion
Most of the recent developments in breast cancer therapy,
some of which have already been included into clinical practice,
have been shown to improve PFS and RR allowing the possibility
of achieving chronic status in metastatic disease. Unfortunately,
as treatment duration increases, toxicity and resistance to
therapy become more evident, hence justifying the continued
quest for new cytotoxic agents with greater efficacy and
tolerability. The main issue is still toxicity, as most of the
compounds tested have displayed, at best, a distinct adverse
event profile. Overcoming chemotherapy resistance and
identifying predictive markers or subgroups most likely to
respond to these agents should also be better investigated. As it is
already clear that an integrative approach is often the most
effective, the future holds the challenge of best combining
cytotoxic and targeted therapy.
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